Found: 17
Select item for more details and to access through your institution.
Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
- Published in:
- Endocrine (1355008X), 2024, v. 84, n. 2, p. 704, doi. 10.1007/s12020-024-03707-5
- By:
- Publication type:
- Article
SARS-CoV-2 Affects Thyroid and Adrenal Glands: An 18 F-FDG PET/CT Study.
- Published in:
- Biomedicines, 2023, v. 11, n. 11, p. 2899, doi. 10.3390/biomedicines11112899
- By:
- Publication type:
- Article
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements.
- Published in:
- Cancers, 2023, v. 15, n. 11, p. 2975, doi. 10.3390/cancers15112975
- By:
- Publication type:
- Article
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.
- Published in:
- Journal of Nuclear Medicine Technology, 2023, v. 51, n. 1, p. 22, doi. 10.2967/jnmt.122.264904
- By:
- Publication type:
- Article
Nodal Merkel Cell Carcinoma with Unknown Primary Site and No Distant Metastasis: A Single-Center Series.
- Published in:
- Cancers, 2022, v. 14, n. 19, p. 4777, doi. 10.3390/cancers14194777
- By:
- Publication type:
- Article
Tailored Molecular Imaging of Pheochromocytoma and Paraganglioma: Which Tracer and When.
- Published in:
- Neuroendocrinology, 2022, v. 112, n. 10, p. 927, doi. 10.1159/000522089
- By:
- Publication type:
- Article
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [<sup>18</sup>F]FDG PET/CT study.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 10, p. 3419, doi. 10.1007/s00259-022-05801-0
- By:
- Publication type:
- Article
A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3).
- Published in:
- Diagnostics (2075-4418), 2021, v. 11, n. 12, p. 2401, doi. 10.3390/diagnostics11122401
- By:
- Publication type:
- Article
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 10, p. 3260, doi. 10.1007/s00259-021-05236-z
- By:
- Publication type:
- Article
From the Magic Bullet to Theragnostics: Certitudes and Hypotheses, Trying to Optimize the Somatostatin Model.
- Published in:
- Cancers, 2021, v. 13, n. 14, p. 3474, doi. 10.3390/cancers13143474
- By:
- Publication type:
- Article
How Useful Are Tumor Markers in Detecting Metastases with FDG-PET/CT during Breast Cancer Surveillance?
- Published in:
- Oncology, 2020, v. 98, n. 10, p. 714, doi. 10.1159/000507707
- By:
- Publication type:
- Article
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 10, p. 2358, doi. 10.1007/s00259-020-04712-2
- By:
- Publication type:
- Article
Correlation of dose with toxicity and tumour response to <sup>90</sup>Y- and <sup>177</sup>Lu-PRRT provides the basis for optimization through individualized treatment planning.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2018, v. 45, n. 13, p. 2426, doi. 10.1007/s00259-018-4044-x
- By:
- Publication type:
- Article
Radioembolization of hepatic lesiorns from a radiobiology and dosimetric perspective.
- Published in:
- Frontiers in Oncology, 2014, v. 4, p. 1, doi. 10.3389/fonc.2014.00210
- By:
- Publication type:
- Article
Peptide receptor radionuclide therapy with <sup>90</sup>Y-DOTATOC in recurrent meningioma.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2009, v. 36, n. 9, p. 1407, doi. 10.1007/s00259-009-1115-z
- By:
- Publication type:
- Article
High-Dose Radioimmunotherapy with <sup>90</sup>Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment.
- Published in:
- Journal of Nuclear Medicine, 2007, v. 48, n. 11, p. 1871, doi. 10.2967/jnumed.107.044016
- By:
- Publication type:
- Article